ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,172.40
-1.16%
S&P ASX All Technology
3,708.30
-1.86%
Brent Oil
73.045
0.00%
US Dollar vs AUD
1.61135
0.00%
Bitcoin
84,554.64
0.22%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Prime Medicine Inc (PRME) Share Price

Prime Medicine Inc

Prime Medicine Inc (PRME)

Prim SA
Prim SA
Prim SA
Prim SA
Prime Drink Group Corp
2.52
0.10
(4.13%)
Closed 01 March 8:00AM
Delayed by 15 minutes
2.57
0.05
(1.98%)
After Hours: 10:49AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.57
Bid
2.35
Offer
2.78
Volume
974,176
2.33 Day's Range 2.55
2.25 52 Week Range 9.62
Market Cap
337.083M
Previous Close
2.42
Open
2.41
Last Trade
2000
@
2.57
(formt)
Last Trade Time
Financial Volume
US$ 2,401,377
VWAP
2.465
Average Volume (3m)
1,057,369
Shares Outstanding
131,160,842
Dividend Yield
-
PE Ratio
-1.67
Earnings Per Share (EPS)
-1.51
Revenue
-
Net Profit
-198.13M

About Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.primemedicine.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was US$2.42. Over the last year, Prime Medicine shares have traded in a share price range of US$ 2.25 to US$ 9.62.

Prime Medicine currently has 131,160,842 shares in issue. The market capitalisation of Prime Medicine is US$317.41 million. Prime Medicine has a price to earnings ratio (PE ratio) of -1.67.

Ask ADVFN Intelligence (AI)

PRME Latest News

More News

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
22 hours ago
PRME (4.13%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
22 hours ago
PRME (4.13%)

Form 8-K - Current report
Edgar (US Regulatory)
22 hours ago
PRME (4.13%)

Form 8-K - Current report
Edgar (US Regulatory)
14 January 2025
PRME (4.13%)

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
23 December 2024
PRME (4.13%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
14 December 2024
PRME (4.13%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.61-19.18238993713.183.19542.419174542.69275598CS
4-0.3-10.45296167252.873.362.2510729262.70965552CS
12-0.43-14.333333333333.592.2510573692.87828506CS
26-1.72-40.09324009324.295.022.2512946893.44753274CS
52-6.64-72.0955483179.219.622.2510321314.41785235CS
156-16.4-86.452293094418.9721.73012.256673406.86879873CS
260-16.4-86.452293094418.9721.73012.256673406.86879873CS

PRME - Frequently Asked Questions (FAQ)

What is the current Prime Medicine share price?
The current share price of Prime Medicine is US$ 2.57
How many Prime Medicine shares are in issue?
Prime Medicine has 131,160,842 shares in issue
What is the market cap of Prime Medicine?
The market capitalisation of Prime Medicine is USD 317.41M
What is the 1 year trading range for Prime Medicine share price?
Prime Medicine has traded in the range of US$ 2.25 to US$ 9.62 during the past year
What is the PE ratio of Prime Medicine?
The price to earnings ratio of Prime Medicine is -1.67
What is the reporting currency for Prime Medicine?
Prime Medicine reports financial results in USD
What is the latest annual profit for Prime Medicine?
The latest annual profit of Prime Medicine is USD -198.13M
What is the registered address of Prime Medicine?
The registered address for Prime Medicine is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Prime Medicine website address?
The website address for Prime Medicine is www.primemedicine.com
Which industry sector does Prime Medicine operate in?
Prime Medicine operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAKSTAK Inc
US$ 3.97
(156.13%)
174.23k
ORGOOrganogenesis Holdings Inc
US$ 6.21
(102.28%)
59M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
ARBBARB IOT Group Ltd
US$ 0.6635
(38.23%)
59.08M
NVNINVNI Group Ltd
US$ 0.99
(-50.50%)
72.79M
SPGCSacks Parente Golf Inc
US$ 0.2085
(-48.65%)
58.21M
ADGMAdagio Medical Holdings Inc
US$ 0.8081
(-47.53%)
756.76k
PRAXPraxis Precision Medicines Inc
US$ 38.60
(-40.64%)
3.2M
SAGSAG Holdings Ltd
US$ 1.19
(-38.97%)
789.86k
NVDANVIDIA Corporation
US$ 124.92
(3.97%)
389.48M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.44
(7.78%)
154.46M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.18M
LCIDLucid Group Inc
US$ 2.22
(-0.45%)
136.17M

PRME Discussion

View Posts
Monksdream Monksdream 2 months ago
PRME, under $

👍️0
PonkenPlonken PonkenPlonken 3 months ago
Super super undervalued..
Recent PSTX - Roche deal should have made this run? Atleast given it also recently partnered with BMS... makes zero sense.
Is a clear validation CRISPR genome editing is hot in cancer cell therapy.
Waiting for a sign....
👍️0
Monksdream Monksdream 4 months ago
PRME under $5
👍️0
Monksdream Monksdream 5 months ago
PRME new 52 week low
👍️0
Invest-in-America Invest-in-America 5 months ago
PRME: Glad I grabbed a chunk of THIS ONE!!!!
👍️0
PonkenPlonken PonkenPlonken 5 months ago
"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the “Offering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
👍️0
Monksdream Monksdream 6 months ago
PRME new 52=week low
👍️0
wiwineguy wiwineguy 6 months ago
K. I'm in!
👍️0
Monksdream Monksdream 6 months ago
DAKT
👍️0
wiwineguy wiwineguy 6 months ago
You are amazing Monk. Any recommendations
👍️0
Monksdream Monksdream 6 months ago
PRME under $5
👍️0
Monksdream Monksdream 7 months ago
PRME new 52 week low
👍️0
Monksdream Monksdream 7 months ago
PRME under $6
👍️0
Monksdream Monksdream 8 months ago
PRME under $10:
👍️0
Monksdream Monksdream 9 months ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
👍️0
Monksdream Monksdream 9 months ago
PRME under $10
👍️0
jondoeuk jondoeuk 9 months ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
👍️0
NY1972 NY1972 10 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
👍️0
jondoeuk jondoeuk 10 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
👍️0
jondoeuk jondoeuk 1 year ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
👍️0

Your Recent History

NASDAQ
PRME
Prime Medicine
BIT
UC8HXL
Unicredit Bank
BIT
P1SL64
BNP Paribas Issuance
BIT
S29798
Societe Generale Effekten
BIT
XCS2
Australia SSA Bonds UCIT...
BIT
POR
Portobello
BIT
S28307
Societe Generale Effekten
BIT
F30615
Vontobel Financial Produ...
BIT
UC4VF6
Unicredit Bank
BIT
I06733
Intesa Sanpaolo
USOTC
NIOVF
Plato Gold (QB)
LSE
CESG
Ft Cesg
ASX
TLSHZ
Telstra
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads